Literature DB >> 11314023

Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas.

O Fluge1, D R Haugen, L A Akslen, A Marstad, M Santoro, A Fusco, J E Varhaug, J R Lillehaug.   

Abstract

Somatic rearrangements of the ret receptor tyrosine kinase have been consistently reported in papillary thyroid carcinomas (PTC). It is unclear whether the expression of wild-type c-ret may also be implicated in thyroid tumorigenesis. We studied ret mRNA expression in PTC from Norwegian patients. Using RT-PCR, wild-type ret mRNA was detected in all of 22 PTC and in a PTC cell line. c-ret mRNA was clearly overexpressed in PTC as compared to non-neoplastic thyroid tissue. Hybridization using ret exon DNA dot blot arrays and complex cDNA probes confirmed expression of ret RNA in thyroid biopsies. In accordance with the RNA data, Western immunoblotting showed evidence of wild-type Ret protein in PTC. Rearrangements generating the ret/PTC oncogenes co-existed with c-ret mRNA in PTC. Multiple alternative ret splicing variants were detected in PTC. Four novel ret splicing events were found in the region encoding the extracellular domain. The open reading frames of these transcripts were all in-frame with the Ret tyrosine kinase domain. In the central ret mRNA region encoding the cysteine-rich, transmembrane, and main tyrosine kinase domains, no evidence of alternative splicing was detected. Two alternative splice events were detected in the ret mRNA encoding the C-terminal part of Ret protein harboring tyrosine residues important for Ret signaling, excluding exon 19, or retaining intron 19, respectively. Ribonuclease protection assays confirmed the presence of ret alternative splicing events in thyroid biopsies. We conclude that in addition to ret/PTC rearrangements, wild-type c-ret mRNA and alternatively spliced ret transcripts are present in PTC. Transcriptional up-regulation and post-transcriptional mechanisms of c-ret RNA processing may contribute to differences in expression of Ret protein observed in PTC compared to non-neoplastic thyroid tissue.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11314023     DOI: 10.1038/sj.onc.1204161

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  5 in total

Review 1.  Molecular rearrangements and morphology in thyroid cancer.

Authors:  Todd G Kroll
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

2.  Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas.

Authors:  Teresa Ramone; Cristina Romei; Raffaele Ciampi; Alessia Tacito; Paolo Piaggi; Liborio Torregrossa; Clara Ugolini; Rossella Elisei
Journal:  Endocrine       Date:  2019-07-05       Impact factor: 3.633

3.  Identification and characterization of the human ARD1-NATH protein acetyltransferase complex.

Authors:  Thomas Arnesen; Dave Anderson; Christian Baldersheim; Michel Lanotte; Jan E Varhaug; Johan R Lillehaug
Journal:  Biochem J       Date:  2005-03-15       Impact factor: 3.857

4.  The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.

Authors:  Rosa Marina Melillo; Anna Maria Cirafici; Valentina De Falco; Marie Bellantoni; Gennaro Chiappetta; Alfredo Fusco; Francesca Carlomagno; Antonella Picascia; Donatella Tramontano; Giovanni Tallini; Massimo Santoro
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

5.  Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer.

Authors:  Alfredo Fusco; Gennaro Chiappetta; Pei Hui; Ginesa Garcia-Rostan; Lauren Golden; Barbara K Kinder; Deborah A Dillon; Ada Giuliano; Anna Maria Cirafici; Massimo Santoro; Juan Rosai; Giovanni Tallini
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.